Imagen de Portada

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuwen Lin, Mei Xie, Jie Yao, Xidong Ma, Lin Qin, Xu‐Mei Zhang, Jialin Song, Xinyu Bao, Xin Zhang, Yinguang Zhang, Yiming Liu, Wenya Han, Yiran Liang, Ying Jing, Xinying Xue
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical and Translational Medicine
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
por: Ailing Cao, et al.
Publicado: (2026)

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer
por: Antoine Desilets, et al.
Publicado: (2024)

Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer
por: Ying Cheng, et al.
Publicado: (2024)

Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics
por: Yue Zhao, et al.
Publicado: (2026)

Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non‐small‐cell lung cancer
por: Ke Xu, et al.
Publicado: (2024)

The co‐location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non‐small cell lung cancer
por: Guangyu Fan, et al.
Publicado: (2024)

Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer
por: Xiaoshen Zhang, et al.
Publicado: (2024)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
por: Linda Wanika, et al.
Publicado: (2024)

Insights into the mechanisms, regulation, and therapeutic implications of extracellular matrix stiffness in cancer
por: Ximo Zhang, et al.
Publicado: (2024)

Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers
por: Chenglin Yang, et al.
Publicado: (2024)

CXCR5 and TLR4 signals synergistically enhance non‐small cell lung cancer progression
por: Ji Hye Shin, et al.
Publicado: (2024)

Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer
por: Xiao‐dan Wan, et al.
Publicado: (2025)

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights
por: Anqi Lin, et al.
Publicado: (2025)

B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential
por: Zizhuo Li, et al.
Publicado: (2024)

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
por: Luca Marzano, et al.
Publicado: (2024)

Spatial omics accelerate the study of cancer‐associated fibroblasts in non‐small lung cancer
por: Haozhen Liu, et al.
Publicado: (2024)

Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study
por: Boya Zhao, et al.
Publicado: (2024)

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
por: Yu Wang, et al.
Publicado: (2024)

Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study
por: Pulin Li, et al.
Publicado: (2024)

Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
por: Vahid Yaghoubi Naei, et al.
Publicado: (2024)

Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer
por: Haoran Li, et al.
Publicado: (2024)

Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer
por: Yuichiro Suzukawa, et al.
Publicado: (2026)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
por: Weijiao Xu, et al.
Publicado: (2025)

Bridging the gap in OA therapeutics: Bioengineered strategies to target osteoclast–chondrocyte crosstalk
por: Enbo Zhang, et al.
Publicado: (2026)

Inflammatory‐associated myeloid dendritic cells reveals associations between chronic lung diseases and lung cancer
por: Zhiyu Chen, et al.
Publicado: (2024)

Unveiling miR‐451a and miR‐142‐3p as prognostic markers in non‐small cell lung cancer via small extracellular vesicle liquid biopsy
por: Miranda Burdiel, et al.
Publicado: (2026)

Molecular mechanisms of ageing in cancer development and therapeutic response: Translational implications for precision oncology
por: Laiba Husain
Publicado: (2025)

Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells
por: Haoxian Ke, et al.
Publicado: (2025)

Anti‐PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest
por: Mengjia Qian, et al.
Publicado: (2025)

Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy
por: Li Li, et al.
Publicado: (2024)

Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non‐small cell lung cancer
por: Jie Tang, et al.
Publicado: (2024)

Engineering exosomes for Alzheimer's disease: Multi‐target therapeutic strategies from pathogenesis to clinical translation
por: Yuehan Zhang, et al.
Publicado: (2025)

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
por: Huanxiang Chen, et al.
Publicado: (2024)

Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer
por: Pei Lin, et al.
Publicado: (2025)

Persistent lineage plasticity driving lung cancer development and progression
por: Fanchen Meng, et al.
Publicado: (2025)

Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer
por: Liuer He, et al.
Publicado: (2024)

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance
por: Junyan Li, et al.
Publicado: (2026)

High‐risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database
por: Weili Kong, et al.
Publicado: (2024)

Investigating the biological effects of socioeconomic adversity in cancer
por: David Füller
Publicado: (2024)

Glutamate as a therapeutic strategy to promote liver regeneration
por: María del Mar Rigual, et al.
Publicado: (2025)